Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
Opt Express ; 25(13): 15336-15348, 2017 Jun 26.
Artigo em Inglês | MEDLINE | ID: mdl-28788961

RESUMO

The trade-off between the spectral bandwidth and average output power from chalcogenide fiber-based mid-infrared supercontinuum sources is one of the major challenges towards practical application of the technology. In this paper we address this challenge through tapering of large-mode-area chalcogenide photonic crystal fibers. Compared to previously reported step-index fiber tapers the photonic crystal fiber structure ensures single-mode propagation, which improves the beam quality and reduces losses in the taper due to higher-order mode stripping. By pumping the tapered fibers at 4 µm using a MHz optical parametric generation source, and choosing an appropriate length of the untapered fiber segments, the output could be tailored for either the broadest bandwidth from 1 to 11.5 µm with 35.4 mW average output power, or the highest output power of 57.3 mW covering a spectrum from 1 to 8 µm.

2.
Opt Express ; 24(11): 12406-13, 2016 May 30.
Artigo em Inglês | MEDLINE | ID: mdl-27410155

RESUMO

A more than 1.5 octave-spanning mid-infrared supercontinuum (1.2 to 3.6 µm) is generated by pumping a As2S3-silica "double-nanospike" waveguide via a femtosecond Cr:ZnS laser at 2.35 µm. The combination of the optimized group velocity dispersion and extremely high nonlinearity provided by the As2S3-silica hybrid waveguide enables a ~100 pJ level pump pulse energy threshold for octave-spanning spectral broadening at a repetition rate of 90 MHz. Numerical simulations show that the generated supercontinuum is highly coherent over the entire spanning wavelength range. The results are important for realization of a high repetition rate octave-spanning frequency comb in the mid-infrared spectral region.

3.
Opt Express ; 24(8): 7977-86, 2016 Apr 18.
Artigo em Inglês | MEDLINE | ID: mdl-27137239

RESUMO

A highly birefringent polarization-maintaining chalcogenide microstructured optical fiber (MOF) covering the 3-8.5 µm wavelength range has been realized for the first time. The fiber cross-section consists of 3 rings of circular air holes with 2 larger holes adjacent to the core. Birefringence properties are calculated by using the vector finite-element method and are compared to the experimental ones. The group birefringence is 1.5x10-3 and fiber losses are equal to 0.8 dB/m at 7.55 µm.

4.
Opt Express ; 23(3): 3282-91, 2015 Feb 09.
Artigo em Inglês | MEDLINE | ID: mdl-25836186

RESUMO

A low-loss suspended core As(38)Se(62) fiber with core diameter of 4.5 µm and a zero-dispersion wavelength of 3.5 µm was used for mid-infrared supercontinuum generation. The dispersion of the fiber was measured from 2.9 to 4.2 µm and was in good correspondence with the calculated dispersion. An optical parametric amplifier delivering 320 fs pulses with a peak power of 14.8 kW at a repetition rate of 21 MHz was used to pump 18 cm of suspended core fiber at different wavelengths from 3.3 to 4.7 µm. By pumping at 4.4 µm with a peak power of 5.2 kW coupled to the fiber a supercontinuum spanning from 1.7 to 7.5 µm with an average output power of 15.6 mW and an average power >5.0 µm of 4.7 mW was obtained.

5.
Opt Lett ; 39(17): 5216-9, 2014 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-25166113

RESUMO

A double-nanospike As2S3-silica hybrid waveguide structure is reported. The structure comprises nanotapers at input and output ends of a step-index waveguide with a subwavelength core (1 µm in diameter), with the aim of increasing the in-coupling and out-coupling efficiency. The design of the input nanospike is numerically optimized to match both the diameter and divergence of the input beam, resulting in efficient excitation of the fundamental mode of the waveguide. The output nanospike is introduced to reduce the output beam divergence and the strong endface Fresnel reflection. The insertion loss of the waveguide is measured to be ∼2 dB at 1550 nm in the case of free-space in-coupling, which is ∼7 dB lower than the previously reported single-nanospike waveguide. By pumping a 3-mm-long waveguide at 1550 nm using a 60-fs fiber laser, an octave-spanning supercontinuum (from 0.8 to beyond 2.5 µm) is generated at 38 pJ input energy.

6.
J Neurochem ; 120 Suppl 1: 186-193, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21883222

RESUMO

Recent advances in the understanding of Alzheimer's disease pathogenesis have led to the development of numerous compounds that might modify the disease process. Amyloid ß (Aß) peptide represents an important molecular target for intervention in Alzheimer's disease. Several types of Aß peptide immunotherapy for Alzheimer's disease are under investigation, direct immunization with synthetic intact Aß(42) , active immunization involving the administration of synthetic fragments of Aß peptide conjugated to a carrier protein and passive administration with monoclonal antibodies directed against Aß peptide. Pre-clinical studies showed that immunization against Aß peptide can provide protection and reversal of the pathology of Alzheimer's disease in animal models. Indeed, several adverse events have been described like meningoencephalitis with AN1792, vasogenic edema and microhemorrhages with bapineuzumab. Although immunotherapy approaches resulted in clearance of amyloid plaques in patients with Alzheimer's disease, this clearance did not show significant cognitive effect for the moment. Currently, several Aß peptide immunotherapy approaches are under investigation but also against tau pathology.


Assuntos
Doença de Alzheimer/imunologia , Doença de Alzheimer/prevenção & controle , Vacinas contra Alzheimer/administração & dosagem , Peptídeos beta-Amiloides/administração & dosagem , Imunoterapia/métodos , Imunoterapia/tendências , Vacinas contra Alzheimer/imunologia , Peptídeos beta-Amiloides/imunologia , Animais , Ensaios Clínicos como Assunto/métodos , Ensaios Clínicos como Assunto/tendências , Modelos Animais de Doenças , Avaliação Pré-Clínica de Medicamentos , Humanos , Vacinação/métodos , Vacinação/tendências
7.
Materials (Basel) ; 7(9): 6120-6129, 2014 Aug 26.
Artigo em Inglês | MEDLINE | ID: mdl-28788180

RESUMO

An original way to obtain fibers with special chromatic dispersion and single-mode behavior is to consider microstructured optical fibers (MOFs). These fibers present unique optical properties thanks to the high degree of freedom in the design of their geometrical structure. In this study, the first all-solid all-chalcogenide MOFs exhibiting photonic bandgap transmission have been achieved and optically characterized. The fibers are made of an As38Se62 matrix, with inclusions of Te20As30Se50 glass that shows a higher refractive index (n = 2.9). In those fibers, several transmission bands have been observed in mid infrared depending on the geometry. In addition, for the first time, propagation by photonic bandgap effect in an all-chalcogenide MOF has been observed at 3.39 µm, 9.3 µm, and 10.6 µm. The numerical simulations based on the optogeometric properties of the fibers agree well with the experimental characterizations.

8.
CNS Drugs ; 25(3): 213-26, 2011 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-21323393

RESUMO

It has been shown that, during several years preceding the diagnosis of Alzheimer's disease there is a gradual cognitive decline with a continuum between the pre-dementia stage (still known as the prodromal stage but now included within the general concept of mild cognitive impairment [MCI]) and the other stages of the disease. In MCI, the use of cholinesterase inhibitors (ChEIs) is not associated with any delay in the onset of Alzheimer's disease or dementia. During the dementia stages, the three ChEIs (donepezil, galantamine and rivastigmine) are efficacious for mild to moderate Alzheimer's disease; therefore, monotherapy with a ChEI can be envisaged as initial treatment. Confirmation of the efficacy of ChEIs in the mild dementia stage is essentially based on the results from a single, randomized study carried out specifically among patients at this stage of severity. Memantine can represent an alternative to ChEIs in the moderate stage of Alzheimer's disease. At the severe stage of the disease, memantine and donepezil are currently indicated. Indeed, memantine has been approved by numerous drug regulatory agencies for use in severe stages of the disease, whereas donepezil has only been approved by the US FDA. There is currently insufficient evidence for recommending combination therapy in Alzheimer's disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Inibidores da Colinesterase/uso terapêutico , Transtornos Cognitivos/tratamento farmacológico , Doença de Alzheimer/psicologia , Transtornos Cognitivos/etiologia , Continuidade da Assistência ao Paciente , Donepezila , Humanos , Indanos/uso terapêutico , Memantina/uso terapêutico , Piperidinas/uso terapêutico , Ensaios Clínicos Controlados Aleatórios como Assunto
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA